Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
7.45
Nov 20 • 3:59 PM ET Dollar change-0.15 Percentage change(-1.97%)
Aftermarket Close
7.55
Aftermarket • 7:30 PM ET Dollar change+0.10 Percentage change(1.34%)
Index
RUT
Market Cap
214.73M
Enterprise Value
51.77M
Income
-87.24M
Sales
21.42M
Book/sh
5.93
Cash/sh
6.41
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
111
IPO
May 22, 2013
P/E
-
Forward P/E
-
PEG
-
P/S
10.02
P/B
1.26
P/C
1.16
P/FCF
-
EV/EBITDA
-
EV/Sales
2.42
Quick Ratio
6.68
Current Ratio
6.68
Debt/Eq
0.13
LT Debt/Eq
0.11
Option/Short
Yes / Yes
EPS (ttm)
-3.08
EPS next Y
-3.46
EPS next Q
-0.82
EPS this Y
-21.90%
EPS next Y
-18.14%
EPS next 5Y
-11.57%
EPS past 3/5Y
- 7.53%
Sales past 3/5Y
-31.15% 47.77%
EPS Y/Y TTM
-25.04%
Sales Y/Y TTM
-74.84%
EPS Q/Q
47.29%
Sales Q/Q
19.07%
Insider Own
8.36%
Insider Trans
0.00%
Inst Own
82.16%
Inst Trans
1.51%
ROA
-35.06%
ROE
-44.37%
ROIC
-46.66%
Gross Margin
88.14%
Oper. Margin
-463.82%
Profit Margin
-407.24%
SMA20
-21.73%
SMA50
-36.43%
SMA200
-18.29%
Trades
Shs Outstand
28.46M
Shs Float
26.41M
52W High
17.96 -58.52%
52W Low
5.50 35.45%
Volatility
10.59% 10.60%
ATR (14)
0.98
RSI (14)
33.07
Beta
2.69
Rel Volume
0.66
Avg Volume
908.92K
Volume
602,023
Perf Week
-10.89%
Perf Month
-30.57%
Perf Quarter
-48.05%
Perf Half Y
5.97%
Perf YTD
21.53%
Perf Year
26.27%
Perf 3Y
-69.44%
Perf 5Y
-79.56%
Perf 10Y
-47.57%
Prev Close
7.60
Price
7.45
Change %
-1.97%
Consensus
Strong Buy
Avg. Price Target
$23.70
Implied Upside
+218.1%
Analysts15incl. previous ratings
Rating Distribution10 Buy · 3 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 24, 2026Upgrade
C logoCCitigroup
Neutral → Buy$20+168.5%
Mar 18, 2026Initiated
RILY logoRB. Riley Securities
Buy$22+195.3%
Jan 23, 2026Initiated
RRoth Capital
Buy$20+168.5%
Oct 24, 2025Downgrade
HH.C. Wainwright
Buy → Neutral$12+61.1%
Oct 23, 2025Downgrade
C logoCCitigroup
Buy → Neutral$12+61.1%
Oct 22, 2025Downgrade
GGuggenheim
Buy → Neutral
Sep 04, 2025Resumed
HH.C. Wainwright
Buy$60+705.4%
May 28, 2025Initiated
BNS logoBScotiabank
Sector Outperform$32+329.5%
Jan 28, 2025Initiated
BBTIG Research
Buy$41+450.3%
Aug 12, 2024Initiated
LLeerink Partners
Outperform$70+839.6%
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
FounderMr. Joseph E. Payne M.Sc.
FounderDr. Padmanabh Chivukula Ph.D.
Principal Accounting Officer & ControllerMr. Joseph Roberts
Chief Legal OfficerMr. Lance Kurata
Chief Financial OfficerMr. Dennis M. Mulroy